Business Context and Reporting Period
This Form 6-K filing by Gold Fields Limited, a South African gold mining company, covers the month of April 2009. The report discloses a material transaction regarding executive compensation approved on March 2, 2009, and accepted by recipients on March 31, 2009.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a share-based compensation plan rather than financial performance results.
Material Changes and Transaction Details
The primary material event is the grant of Share Appreciation Rights (SARS) and Performance Vesting Restricted Shares (PVRS) to directors and company secretaries. Key terms include:
- SARS: Granted with a fixed strike price of R109.66. They vest after three years with a three-year exercise window. Settlement may be in cash or shares.
- PVRS: Granted at a zero strike price. Vesting is contingent on performance criteria measured over three years, specifically targeting a percentage of expected gold production. Awards may increase by up to 300% based on peer group performance.
- Recipients: Grants were made to the CEO (N.J. Holland), three directors (I. Boninelli, V.P. Pillay, D. Roets), and two company secretaries (C. Farrel, P.B. Beale).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on market outlook, or specific risk factors. The only performance metric mentioned is the internal target for gold production used to determine PVRS settlement.
Investor Verification Checklist
- Verify the total number of SARS and PVRS granted to ensure alignment with the company's long-term incentive plan limits.
- Confirm the specific "Target Performance Criteria" percentage for gold production required for PVRS vesting.
- Review the company's subsequent 20-F or 40-F filings to assess the dilution impact of these grants on existing shareholders.
- Check the current share price relative to the R109.66 SARS strike price to evaluate the immediate intrinsic value of the awards.